Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA TrialBarry A. Borlaug, Rickey E. Carter, Michael D. Jensen et al.|Circulation|2023Cited by 116
Ventricular Stiffening and Chamber Contracture in Heart Failure with Higher Ejection FractionDejana Popović, Barry A. Borlaug, Hidemi Sorimachi et al.|European Journal of Heart Failure|2023Cited by 65
Dapagliflozin and Right Ventricular–Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection FractionYogesh N.V. Reddy, Barry A. Borlaug, Michael D. Jensen et al.|JAMA Cardiology|2024Cited by 40
Prognostic Value of Coronary Flow Reserve in Asymptomatic Moderate or Severe Aortic Stenosis with Preserved Ejection Fraction and Nonobstructed Coronary ArteriesMarko Banović, Nikolic Serjan, Ivana Nedeljković et al.|Echocardiography|2013Cited by 36
Hypoxaemia in Patients with Heart Failure and Preserved Ejection FractionMassar Omar, Barry A. Borlaug, Sanjiv J. Shah et al.|European Journal of Heart Failure|2023Cited by 24